hepatocellular carcinoma
Conditions
Interventions
Gold Standard:SonoVue
Index test:Sonazoid
Sponsors
The First Medical Centre, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Older than 18 years old; 2. Patients have been diagnosed with liver cirrhosis or chronic hepatitis, and is currently undergoing diagnosis/exclusion assessment of HCC; 3. In the 30 days before enrollment in the study, target lesion (at least one FLL >= 1 cm but not greater than 3 cm) was determined in the ultrasound (US) examination, and the lesion needs to be further examined for qualitative diagnosis; 4. Patients Plan to undergo surgery or biopsy of the target lesion, or plan to perform other imaging examinations (CT and/or MRI) to obtain independent reference standards; 5. Obtain informed consent of patients for examination and treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with liver cirrhosis caused by congenital liver fibrosis or vascular disease; 2. The target lesion has been treated (local treatment); 3. According to the product specification, the patient has contraindications to one or two study drug injections; 4. Participated in this study; 5. Pregnant or lactating women; 6. There are any medical conditions or other conditions that will significantly reduce the availability of reliable data, achieve research goals, or complete the research and/or follow-up evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characteristics of routine ultrasound in liver lesion;Characteristics of contrast-enhanced ultrasound in liver lesion; | — |
Countries
China
Contacts
Public ContactFei Xiang
The First Medical Centre, Chinese PLA General Hospital
Outcome results
None listed